The U.S. healthcare system is no stranger to policy turbulence, but the latest HHS shakeup has sent shockwaves through the pharmaceutical sector — particularly in the arena of ED policy. For Fildena users, this leadership turnover raises critical questions about regulatory continuity, market access, and how federal-state policy differences may shape availability in the coming months....
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek